Practical Approaches to Treatment in Breast Cancer

In 2 workshops moderated by Mark Pegram, MD, and Joyce A. O'Shaughnessy, MD, oncologists who specialize in the treatment of breast cancer met to discuss best practices for biomarker testing, the emerging concept of HER2-low BC, and treatment approaches for BC throughout the course of the disease. This article summarizes key takeaways and stakeholder insights from these workshops.

Joyce A. O’Shaughnessy, MD, discusses the sequencing of pembrolizumab with chemotherapy in patients with early-stage triple-negative breast cancer.

Paolo Tarantino, MD, researcher, the European Institute of Oncology; clinical research fellow, Dana-Farber Cancer Institute, discusses the options available in the second line for patients with HER2-positive metastatic breast cancer.